News and Analysis

Iksuda Therapeutics procures $47m

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates, has raised $47 million in funding.

-

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates, has raised $47 million in funding. The investors included Mirae Asset Capital.

Source: Press Release